RE: Good rns or bad31 Jul 2018 21:53
"Early stage of operations
The Company's operations are at an early stage of development and there can be no guarantee that the Company will be able to, or that it will be commercially advantageous for the Company to, develop its proprietary technology and acquire scientific assets. Further, the Company has no positive operating cash flow and its ultimate success will depend on the Board's' ability to implement the Company's strategy, generate cash flow and access equity markets. Whilst the Board is optimistic about the Company's prospects, there is no certainty that anticipated outcomes and sustainable revenue streams will be achieved.
The Company will not generate any material income until commercialisation or licensing of its scientific assets has successfully commenced and in the meantime the Company will continue to expend its cash reserves. There can be no assurance that the Company's proposed operations will be profitable or produce a reasonable return, if any, on investment"
Technology and products
The Company is a drug discovery and development Company. The development and commercialisation of its scientific assets, will require research progress and positive results from multiple clinical trials, which by their very nature are inherently uncertain.
There is a risk that safety issues may arise when the products are tested. This risk is common to all new classes of drugs and, as with all other drug companies, there is a risk that trials may not be successful. The Board takes steps to ensure that all research partners adhere to industry standard guidelines.
Research and development risk
The Company operates in the life sciences and biopharmaceutical development sector and will be looking to exploit opportunities within that sector. The Company is therefore involved in complex scientific research, and industry experience indicates that there may be a very high incidence of delay or failure to produce results. The Company may not be able to develop new products or to identify specific market needs that can be addressed by technology solutions developed by the Company.
The ability of the Company to develop new technology relies, in part, on the recruitment of appropriately qualified staff as the Company grows, or to identify and collaborate with high quality scientific teams and investigators. The Company may be unable to find a sufficient number of appropriately highly trained individuals to satisfy its growth rate which could affect its ability to develop as planned.
Product development timelines:
Product development timelines are at risk of delay, particularly since it is not always possible to predict the rate of patient recruitment into clinical trials. There is a risk therefore that product development could take longer than presently expected; if such delays occur the Company may require further working capital. The Company will seek to minimise the risk of delays by careful management of projects.